Image_3_Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis.tiff

IntroductionPancreatic cancer is a highly aggressive malignancy with limited response to chemotherapy. This research aims to compare the effectiveness and safety of regional intra-arterial chemotherapy (RIAC) with conventional systemic chemotherapy in treating advanced stages of pancreatic cancer.MethodsA comprehensive literature review was conducted using databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Studies assessing the comparative outcomes of RIAC and systemic chemotherapy were included. Data extraction and quality evaluation were performed independently by two researchers. Statistical analysis was conducted using STATA16 software, calculating odds ratios (OR), risk differences (RD), and 95% confidence intervals (CI).ResultsEleven studies, comprising a total of 627 patients, were included in the meta-analysis. The findings showed that patients undergoing RIAC had significantly higher rates of partial remission (PR) compared to those receiving systemic chemotherapy (OR = 2.23, 95% CI: 1.57, 3.15, I2= 0%). Additionally, the rate of complications was lower in the RIAC group (OR = 0.45, 95% CI: 0.33, 0.63, I2= 0%). Moreover, patients treated with RIAC had notably longer median survival times.DiscussionThe results of this research indicate that RIAC is associated with a higher rate of partial remission, improved clinical benefits, and fewer complications compared to systemic chemotherapy in the management of advanced pancreatic cancer. These findings suggest that RIAC may be a more effective and safer treatment option for patients with advanced stages of pancreatic cancer.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023404637.</p

Image_1_Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis.tiff

IntroductionPancreatic cancer is a highly aggressive malignancy with limited response to chemotherapy. This research aims to compare the effectiveness and safety of regional intra-arterial chemotherapy (RIAC) with conventional systemic chemotherapy in treating advanced stages of pancreatic cancer.MethodsA comprehensive literature review was conducted using databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Studies assessing the comparative outcomes of RIAC and systemic chemotherapy were included. Data extraction and quality evaluation were performed independently by two researchers. Statistical analysis was conducted using STATA16 software, calculating odds ratios (OR), risk differences (RD), and 95% confidence intervals (CI).ResultsEleven studies, comprising a total of 627 patients, were included in the meta-analysis. The findings showed that patients undergoing RIAC had significantly higher rates of partial remission (PR) compared to those receiving systemic chemotherapy (OR = 2.23, 95% CI: 1.57, 3.15, I2= 0%). Additionally, the rate of complications was lower in the RIAC group (OR = 0.45, 95% CI: 0.33, 0.63, I2= 0%). Moreover, patients treated with RIAC had notably longer median survival times.DiscussionThe results of this research indicate that RIAC is associated with a higher rate of partial remission, improved clinical benefits, and fewer complications compared to systemic chemotherapy in the management of advanced pancreatic cancer. These findings suggest that RIAC may be a more effective and safer treatment option for patients with advanced stages of pancreatic cancer.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023404637.</p

Image_2_Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis.tiff

IntroductionPancreatic cancer is a highly aggressive malignancy with limited response to chemotherapy. This research aims to compare the effectiveness and safety of regional intra-arterial chemotherapy (RIAC) with conventional systemic chemotherapy in treating advanced stages of pancreatic cancer.MethodsA comprehensive literature review was conducted using databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Studies assessing the comparative outcomes of RIAC and systemic chemotherapy were included. Data extraction and quality evaluation were performed independently by two researchers. Statistical analysis was conducted using STATA16 software, calculating odds ratios (OR), risk differences (RD), and 95% confidence intervals (CI).ResultsEleven studies, comprising a total of 627 patients, were included in the meta-analysis. The findings showed that patients undergoing RIAC had significantly higher rates of partial remission (PR) compared to those receiving systemic chemotherapy (OR = 2.23, 95% CI: 1.57, 3.15, I2= 0%). Additionally, the rate of complications was lower in the RIAC group (OR = 0.45, 95% CI: 0.33, 0.63, I2= 0%). Moreover, patients treated with RIAC had notably longer median survival times.DiscussionThe results of this research indicate that RIAC is associated with a higher rate of partial remission, improved clinical benefits, and fewer complications compared to systemic chemotherapy in the management of advanced pancreatic cancer. These findings suggest that RIAC may be a more effective and safer treatment option for patients with advanced stages of pancreatic cancer.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023404637.</p

Forest plot of WMDs for the comparison between dental age using Demirjian’s method and chronological age among boys (A) and girls (B).

<p>Forest plot of WMDs for the comparison between dental age using Demirjian’s method and chronological age among boys (A) and girls (B).</p

Forest plots of association between cyclin D1 overexpression with poor OS in OSCC.

<p>Forest plots of association between cyclin D1 overexpression with poor OS in OSCC.</p

Studies selection flowchart.

<p>Studies selection flowchart.</p

Characteristics of the included studies in this meta-analysis.

<p>M/F: Male/Female; NA: not available.</p

Begg’s funnel plots for publication bias in cyclin D1 overexpression and clinicopathological outcome in OSCC.

<p>Each point represents a separate study for the indicated estimate; the area of each circle represents the sample size. s.e: standard error; Horizontal line: effect size. (A). Funnel plots of publications for the association between cyclin D1 overexpression and nodal metastasis, random-effects model. B. Funnel plots of publications for the association between cyclin D1 overexpression and histological grade, Peto one-step model.</p

Meta-analysis results of association between cyclin D1 overexpression and clinicopathological outcomes in OSCC.

<p>N.: Number; Stat.: Statistic models; R: random-effects model; F: fixed-effects model; P: Peto one-step method; OR: odds ratio; 95% CI: 95% confidence intervals; p_Z: p value of statistic Z; p_Het: p value of heterogeneity chi-squared; p_Z <0.05 was regarded as significant; p_Het <0.1 was regarded as significant.</p

Forest plots of association between cyclin D1 overexpression with poor clinicopathological outcome in OSCC.

<p>(A). Tumor size, random-effects model; (B). Nodal metastasis, Peto one-step model; C. Histological grade, random-effects model; D. Clinical stage, fixed-effects model.</p